Xaira Therapeutics is an ambitious artificial intelligence endeavor, with founding investors ARCH Venture Partners and Foresite Capital aiming to assemble all components of an AI-powered drug discovery and development operation under one roof – everything from target identification and antibody design to clinical trial planning and patient selection. The start-up also aims to advance its first drug candidates toward the clinic while continuing to build out its datasets and technical capabilities, which is why it launched with ambitious funding – more than $1bn.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
More from AI
• By
The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.
• By
Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?
• By
Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process
• By
Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.
More from Digital Technologies
• By
Amgen’s AI model to predict proteins in the “bright Goldilocks zone of viscosity” with over 80% accuracy minus a wet lab experiment holds immense potential, VP Research Haldar said at an event as he spoke about a “hinge moment” for AI in pharma
• By
MSD's chief information & digital officer emphasizes the need for pharma to accelerate technology adoption cycles to ensure drugs reach patients faster. The role of a robust digital backbone for seamless data flow, leadership commitment in digital transformation and an upcoming technology center in Hyderabad are other aspects he discussed.
• By
CEOs of top Indian firms discuss how policies and geopolitics could shape future manufacturing networks and also the simmering issue of tariffs. US President Donald Trump has just reiterated plans for reciprocal tariffs at a joint session of Congress.